MedPath

Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

Phase 2
Completed
Conditions
Prostatic Neoplasms
Registration Number
NCT00031187
Lead Sponsor
Seagen Inc.
Brief Summary

SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory prostate cancer who have not had any prior therapy with Taxotere or Novantrone. Both SGN-15 and Taxotere will be administered weekly over two 6 week courses separated by a 2 week rest period.

Detailed Description

The purpose of this study is to evaluate a new class of biologic agent, the monoclonal antibody (mAb) drug conjugate SGN-15 (cBR96 - Doxorubicin immunoconjugate), used in combination with the taxane agent, TAXOTERE (docetaxel) as a strategy for targeting advanced stage, hormone refractory prostate carcinoma (HRPC). This is a randomized, open label, phase II study evaluating the immunoconjugate SGN-15 in combination with the taxane TAXOTERE in comparison to TAXOTERE alone in patients with HRPC. Based on a previous phase I study of the SGN-15/TAXOTERE combination, the weekly dose of SGN-15 will be 200 mg/m2 and the weekly dose of TAXOTERE will be 35 mg/m2. The schedule of administration for both agents will be weekly, with SGN-15 administered prior to the TAXOTERE in the patients treated with the combination. A single course of therapy will be defined as 6 weekly doses followed by a 2 week rest period for a total of 8 weeks. The study will perform an interim analysis of the data after 80 patients have completed two courses. Patients should be treated for a minimum of 2 courses of therapy. Additionally, for patients who remain eligible and have experienced tolerable levels of drug toxicity, repeat dosing with subsequent cycles is possible. Patients will be removed from study if there is evidence of tumor progression or intolerable toxicity. Follow-up assessments include adverse event reporting, clinical laboratory studies, and quality of life (QOL) assessment using a validated QOL instrument.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
160
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (11)

Bendheim Cancer Center

🇺🇸

Greenwich, Connecticut, United States

Arlington Fairfax Hematology-Oncology, P.C.

🇺🇸

Arlington, Virginia, United States

Innovative Medical Research of South Florida

🇺🇸

Miami Shores, Florida, United States

Florida Cancer Specialists

🇺🇸

Fort Myers, Florida, United States

VA Medical Center of Palo Alto

🇺🇸

Palo Alto, California, United States

Arizona Cancer Center

🇺🇸

Tucson, Arizona, United States

Highlands Oncology Group

🇺🇸

Springdale, Arkansas, United States

Sharp HealthCare, Sidney Kimmel Cancer Center

🇺🇸

San Diego, California, United States

Broward Oncology Associates

🇺🇸

Ft. Lauderdale, Florida, United States

St. Joseph Mercy Oakland Hospital

🇺🇸

Pontiac, Michigan, United States

West Los Angeles - VA Healthcare Center

🇺🇸

Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath